Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Andexanet Alfa for Urgent Reversal of Apixaban Before Aortic Surgery Requiring Cardiopulmonary Bypass: A Case Report

Flaherty, Devon MD*; Connors, Jean M. MD; Singh, Steve MD; Sylvester, Katelyn W. PharmD§; Rimsans, Jessica PharmD, BCPS§; Cornella, Lauren MD*

doi: 10.1213/XAA.0000000000001052
Case Reports
Buy

Andexanet alfa is a recombinant factor Xa decoy molecule capable of reversing direct and indirect factor Xa–inhibiting anticoagulants. We present an adult patient on apixaban for nonvalvular atrial fibrillation who required urgent reoperative aortic surgery for an aortic root pseudoaneurysm. Apixaban was reversed with andexanet alfa. A second dose of andexanet alfa was required before surgical incision for persistently elevated antifactor Xa levels. Intraoperative management required use of cardiopulmonary bypass (CPB). No major adverse cardiovascular, cerebrovascular, hemorrhagic, or thromboembolic events were observed.

From the *Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women’s Hospital, Boston, Massachusetts

Division of Hematology, Brigham and Women’s Hospital, Boston, Massachusetts

Division of Cardiac Surgery, Trillium Health Partners, University of Toronto, Toronto, Ontario, Canada

§Division of Pharmacy, Brigham and Women’s Hospital, Boston, Massachusetts.

Accepted for publication May 13, 2019.

The authors declare no conflicts of interest.

Funding: None.

Address correspondence to Devon Flaherty, MD, Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. Address e-mail to flaherdc@gmail.com.

Copyright © 2019 International Anesthesia Research Society
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website